SteinCares and Shilpa Biologicals Strike Licensing Deal for Biosimilars in Latin America

Partnership aims to expand patient access to cost-effective treatments across the region

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a biopharmaceutical subsidiary of Shilpa Medicare Limited, have announced a strategic licensing agreement to commercialize a biosimilar across Latin America. Under the deal, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar in the region, while SBPL will handle product development and manufacturing from its facility in India. The partnership combines SBPL's expertise in biologics development and manufacturing with SteinCares' integrated regional platform and market knowledge.

Why it matters

This agreement reinforces SteinCares' leadership in biosimilars and its role as a strategic partner for global biopharmaceutical companies seeking to enter Latin America's complex healthcare markets. By combining Shilpa's capabilities in biologics with SteinCares' regional platform, the collaboration aims to expand patient access to innovative, cost-effective treatments across Latin America.

The details

The partnership marks the first product from this strategic alliance and Shilpa Biologicals' entry into the Latin American market. Under the agreement, SteinCares will be responsible for registering, commercializing, and distributing the biosimilar across the region, while SBPL will complete product development and commercial manufacturing from its facility in Dharwad, India.

  • The licensing agreement was announced on February 25, 2026.

The players

SteinCares

A leading specialty healthcare company in Latin America that expands access to innovative treatments across 30 countries in the region.

Shilpa Biologicals Pvt. Ltd. (SBPL)

A fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited, an Indian pharmaceutical company, that offers development, manufacturing, and ready-to-license formulations in immunology, oncology, and ophthalmics.

Mitchell Waserstein

CEO of SteinCares.

Dr. Sridevi Khambhampaty

CEO of Shilpa Biologicals.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to partner with Shilpa Biologicals to bring this biosimilar to Latin America. This agreement reinforces our leadership in biosimilars and our role as a strategic partner for global biopharmaceutical companies seeking to enter Latin America's complex healthcare markets.”

— Mitchell Waserstein, CEO, SteinCares

“SteinCares is a trusted partner in Latin America with proven expertise in the registration and commercialization of specialty therapies. Through this licensing agreement, we are entering Latin America and aim to broaden patient access to safe treatments across the region.”

— Dr. Sridevi Khambhampaty, CEO, Shilpa Biologicals

What’s next

The partnership aims to expand patient access to the biosimilar product across Latin America through SteinCares' regional commercialization platform.

The takeaway

This collaboration between SteinCares and Shilpa Biologicals reinforces the growing importance of strategic partnerships to expand access to innovative, cost-effective treatments in complex healthcare markets like Latin America.